

Luigi Bolondi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2884260/luigi-bolondi-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

66

papers

3,774

citations

24

h-index

61

g-index

67

ext. papers

4,561

ext. citations

6.5

avg, IF

5.3

L-index

#	Paper	IF	Citations
66	Detoxification of bilirubin and bile acids with intermittent coupled plasmafiltration and adsorption in liver failure (HERCOLE study). <i>Journal of Nephrology</i> , 2021 , 34, 77-88	4.8	1
65	Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020 , 5,	6	21
64	Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 496-499	7	18
63	Hepatocellular adenoma: An unsolved diagnostic enigma. <i>World Journal of Gastroenterology</i> , 2019 , 25, 2442-2449	5.6	9
62	A Western Case of Intravascular Large B-Cell Lymphoma as Unusual Cause of Persistent Fever. <i>Case Reports in Hematology</i> , 2019 , 2019, 1480710	0.7	1
61	Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019 , 7, 69-77	5.3	15
60	Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019 , 72, 28-36	14.4	163
59	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019 , 51, 681-688	3.3	36
58	Long term effects of gluten-free diet in non-celiac wheat sensitivity. <i>Clinical Nutrition</i> , 2019 , 38, 357-363	5.9	14
57	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , 2018 , 19, 682-693	21.7	216
56	New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. <i>Gut</i> , 2018 , 67, 1674-1682	19.2	81
55	MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , 2018 , 120, 95-102	2	16
54	From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. <i>Histopathology</i> , 2018 , 72, 414-422	7.3	4
53	Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 538-546	6.1	26
52	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , 2018 , 24, 3361-3373	5.6	203
51	Outcomes in patients (pts) who had received sorafenib (S) as the only prior systemic therapy in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4088-4088	2.2	6
50	Regorafenib for the treatment of hepatocellular carcinoma. <i>Drugs of Today</i> , 2018 , 54, 5-13	2.5	10

49	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018 , 38, 278-284	7.9	7
48	Celiac Disease Diagnosed through Screening Programs in At-Risk Adults Is Not Associated with Worse Adherence to the Gluten-Free Diet and Might Protect from Osteopenia/Osteoporosis. <i>Nutrients</i> , 2018 , 10,	6.7	5
47	DAA's for HCV and risk of hepatocellular carcinoma: current standpoint. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 736-738	18.8	5
46	Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. <i>Lancet Oncology</i> , 2017 , 18, e101-e112	21.7	87
45	Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. <i>Atherosclerosis</i> , 2017 , 262, 179-184	3.1	14
44	Stereotactic body radiotherapy for patients with hepatocellular carcinoma and intermediate grade cirrhosis - Authors'Reply. <i>Lancet Oncology</i> , 2017 , 18, e193	21.7	
43	Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. <i>Digestive and Liver Disease</i> , 2017 , 49, 802-808	3.3	41
42	Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017 , 4, 129-137	4	15
41	Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. <i>Liver Cancer</i> , 2017 , 6, 337-348	9.1	13
40	miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. <i>Digestive Diseases and Sciences</i> , 2017 , 62, 2397-2407	4	12
39	A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	22
38	Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. <i>Internal and Emergency Medicine</i> , 2016 , 11, 19-30	3.7	9
37	Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2016 , 65, 727-733	13.4	612
36	Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers. <i>Journal of Clinical Pathology</i> , 2016 , 69, 102-8	3.9	7
35	Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. <i>Therapeutic Advances in Gastroenterology</i> , 2016 , 9, 240-9	4.7	56
34	Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016 , 3, 119-136	4	7
33	Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. <i>Digestive and Liver Disease</i> , 2015 , 47, 518-22	3.3	46
32	Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015 , 11, 449-65	3.6	17

31	Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma. <i>Future Oncology</i> , 2015 , 11, 3133-42	3.6	19
30	Clinical and diagnostic aspects of gluten related disorders. <i>World Journal of Clinical Cases</i> , 2015 , 3, 275-84.6		40
29	Contrast-enhanced ultrasound in liver cancer. <i>Hepatic Oncology</i> , 2015 , 2, 51-62	4	3
28	Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2014 , 111, 255-64	8.7	349
27	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , 2014 , 46, 549-55	3.3	43
26	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014 , 32, 4006-4006	2.2	28
25	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014 , 20, 7049-54	5.6	18
24	Early prediction of treatment response to sorafenib with elastosonography in a mice xenograft model of hepatocellular carcinoma: a proof-of-concept study. <i>Ultraschall in Der Medizin</i> , 2013 , 34, 541-9	3.8	6
23	Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. <i>Seminars in Liver Disease</i> , 2012 , 32, 348-59	7.3	387
22	Improved sorafenib activity on hepatocellular carcinoma in Notch3 silenced in vivo and in vitro models.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3061-3061	2.2	
21	From liver cirrhosis to HCC. <i>Internal and Emergency Medicine</i> , 2011 , 6 Suppl 1, 93-8	3.7	20
20	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. <i>Tumori</i> , 2010 , 96, 1028-1030	1.7	11
19	New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. <i>Digestive and Liver Disease</i> , 2007 , 39, 187-95	3.3	62
18	Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 1395-402	6.9	10
17	Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. <i>Hepatology</i> , 2005 , 42, 27-34	11.2	356
16	Review article: liver transplantation for HCC. Treatment options on the waiting list. <i>Alimentary Pharmacology and Therapeutics</i> , 2003 , 17 Suppl 2, 145-50	6.1	21
15	Screening for hepatocellular carcinoma in cirrhosis. <i>Journal of Hepatology</i> , 2003 , 39, 1076-84	13.4	153
14	Tumor dissemination after radiofrequency ablation of hepatocellular carcinoma. <i>Hepatology</i> , 2001 , 34, 608; author reply 610-1	11.2	11

13	Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver. <i>Journal of Medical Virology</i> , 2000 , 62, 25-8	19.7	13
12	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. <i>Hepatology</i> , 2000 , 31, 349-57	11.2	33
11	Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. <i>Hepatology</i> , 2000 , 32, 630-4	11.2	120
10	Splanchnic arterial Doppler parameters in portal hypertension. <i>Hepatology</i> , 1999 , 29, 1610	11.2	1
9	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. <i>Hepatology</i> , 1999 , 30, 58-64	11.2	126
8	Intrahepatic artery pseudoaneurysm: a possible complication of blind thoracentesis. <i>Journal of Clinical Ultrasound</i> , 1999 , 27, 151-5	1	4
7	Duplex Doppler findings in splenic arteriovenous fistula. <i>Journal of Clinical Ultrasound</i> , 1998 , 26, 103-5	1	9
6	Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996 , 41, 800-8	4	8
5	Cigarette smoking, abdominal blood flow and abdominal diseases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1996 , 11, 995-6	4	
4	Cytochemical detection of a class 3 aldehyde dehydrogenase in human hepatocellular carcinoma. <i>Liver</i> , 1995 , 15, 87-92		5
3	Sudden change in the sonographic appearance of a thyroid cyst after percutaneous aspiration. <i>Journal of Clinical Ultrasound</i> , 1989 , 17, 213-5	1	1
2	Morphological and hemodynamic changes in the portal venous system after distal splenorenal shunt: an ultrasound and pulsed Doppler study. <i>Hepatology</i> , 1988 , 8, 652-7	11.2	24
1	Primary gastric lymphoma versus gastric carcinoma: endoscopic US evaluation. <i>Radiology</i> , 1987 , 165, 821-6	20.5	77